Brian Marckx, CFA
Long/short equity

Competitive Advantages, Huge Skin Cancer Market Bode Well For Aura


In July 2010 Verisante Technology (OTCPK:VRSEF) entered a licensing agreement with British Columbia's BC Cancer Agency for use of their cancer detection technology in order to accelerate development of their cancer detection device program. Initial commercialization of the device is focused on the detection of skin cancer, with extensions of the product expected to follow for the detection of other cancers, including lung, gastro-intestinal and cervical.

Skin cancer is a relatively common disease, the incidence of which is on the rise. Since melanoma is progressive and usually fatal in later stages, early detection and removal of cancerous skin lesions is critical to improve patient outcomes. Verisante's patented Aura device has been designed to do just that.


Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details